<DOC>
	<DOCNO>NCT02456103</DOCNO>
	<brief_summary>This open-label extension study patient complete Phase 3 , placebo-controlled study ataluren patient nonsense mutation cystic fibrosis ( nmCF ) receive chronic inhaled aminoglycosides .</brief_summary>
	<brief_title>Extension Study Ataluren Nonsense Mutation Cystic Fibrosis</brief_title>
	<detailed_description />
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Cystic Fibrosis</mesh_term>
	<criteria>Completion study treatment ( placebo active ) previous Phase 3 , doubleblind study protocol ( Protocol PTC124GD021CF ) Ongoing participation therapeutic clinical trial</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2015</verification_date>
</DOC>